7Baggers

Theravance Biopharma, Inc
(NASDAQ:TBPH) 

TBPH stock logo

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstr...

Founded: 2013
Full Time Employees: 316
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 
                                                 
      revenues:
    		                                             
      viatris collaboration agreement
    		17,699,000 20,891,000 19,990,000 18,695,000 15,388,000 18,754,000 16,868,000 14,256,000 14,503,000 17,360,000 15,687,000 13,743,000 10,411,000 14,614,000 12,445,000 10,878,000 10,687,000 12,132,000 10,397,000 10,934,000 10,385,000                         
      total revenues
    		17,699,000 45,891,000 19,990,000 26,195,000 15,388,000 18,754,000 16,868,000                                       
      yoy
    		15.02% 144.70% 18.51%                                           
      qoq
    		-61.43% 129.57% -23.69% 70.23% -17.95% 11.18%                                        
      expenses:
    		                                             
      research and development
    		5,829,000 7,360,000 8,112,000 10,490,000 11,452,000 9,453,000 9,268,000 9,954,000 8,968,000 8,313,000 8,311,000 9,425,000 14,572,000 14,701,000 9,867,000 15,571,000 23,253,000 31,226,000 43,739,000 51,093,000 67,599,000 65,165,000 67,371,000 62,404,000 66,013,000 67,025,000 52,006,000 46,399,000 53,818,000 52,269,000 52,693,000 48,621,000 47,765,000 39,343,000 42,927,000 40,565,000 31,951,000 32,069,000 35,678,000 30,367,000 30,377,000 36,019,000 38,324,000 46,283,000 41,723,000 
      selling, general and administrative
    		17,720,000 18,520,000 18,333,000 18,430,000 18,370,000 18,501,000 16,875,000 17,056,000 16,742,000 15,492,000 16,142,000 19,278,000 19,183,000 15,968,000 16,277,000 16,986,000 19,121,000 21,516,000 21,299,000 25,931,000 30,550,000 30,055,000 27,501,000 24,780,000 26,325,000 33,046,000 25,622,000 22,227,000 25,186,000 25,457,000 21,890,000 25,007,000 24,704,000 20,944,000 24,339,000 20,786,000 20,286,000 20,261,000 23,596,000 22,845,000 21,545,000 21,748,000 17,705,000 13,118,000 19,052,000 
      restructuring expenses
    		3,633,000                                             
      total expenses
    		27,182,000 25,880,000 26,445,000 28,920,000 29,822,000 27,954,000 27,705,000 29,961,000 25,710,000 23,805,000 24,453,000 29,872,000 35,329,000 32,080,000 26,653,000 37,929,000 51,698,000 71,113,000 66,809,000                           
      income from operations
    		-9,483,000 20,011,000 -6,455,000 -2,725,000 -14,434,000 -9,200,000 -10,837,000 -15,705,000 -11,207,000 -6,240,000 -8,760,000 -16,123,000 -24,912,000 -17,431,000 -14,202,000 -26,879,000 -38,502,000 -56,167,000 -53,615,000 -64,110,000 -83,892,000 -76,490,000 -76,615,000 -72,176,000 -72,476,000 -70,572,000 -65,201,000 -42,476,000 -73,666,000 -62,621,000 -62,450,000 -48,704,000 -64,976,000             
      yoy
    		-34.30% -317.51% -40.44% -82.65% 28.79% 47.44% 23.71% -2.59% -55.01% -64.20% -38.32% -40.02% -35.30% -68.97% -73.51% -58.07% -54.11% -26.57% -30.02% -11.18% 15.75% 8.39% 17.51% 69.92% -1.62% 12.70% 4.41% -12.79% 13.37%                 
      qoq
    		-147.39% -410.01% 136.88% -81.12% 56.89% -15.11% -31.00% 40.14% 79.60% -28.77% -45.67% -35.28% 42.92% 22.74% -47.16% -30.19% -31.45% 4.76% -16.37% -23.58% 9.68% -0.16% 6.15% -0.41% 2.70% 8.24% 53.50% -42.34% 17.64% 0.27% 28.22% -25.04%              
      operating margin %
    		-53.58% 43.61% -32.29% -10.40% -93.80% -49.06% -64.25% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      interest expense
    		 -582,000 -573,000 -663,000 -643,000 -643,000 -630,000 -644,000 -629,000 -623,000 -609,000 -568,000 -550,000 -550,000 -1,545,000 -11,884,000 -11,655,000 -11,662,000 -11,742,000 -11,612,000 -11,873,000 -11,680,000 -11,573,000 -11,391,000 -9,941,000 -8,035,000 -8,068,000 -7,901,000 -7,858,000 -4,071,000 -2,137,000 -2,137,000 -2,137,000             
      interest and other income
    		3,013,000 3,639,000 4,139,000 1,457,000 939,000 904,000 1,415,000           338,000 -166,000 1,171,000 -234,000 798,000 1,235,000 -662,000 1,460,000 1,137,000 2,089,000 2,374,000 2,795,000 7,822,000 1,376,000 1,284,000 2,170,000 1,124,000 1,425,000 1,030,000 344,000 308,000 186,000 104,000 204,000 211,000    
      income before income taxes
    		-6,470,000 73,068,000 -2,889,000 73,206,000 -14,138,000 -8,939,000 -10,052,000 -15,221,000 -10,402,000       -8,196,000 -25,422,000 -32,185,000 -35,315,000 -52,625,000 -79,452,000 -67,233,000 -73,550,000 -62,848,000 -82,906,000 -65,557,000 -63,983,000 -39,637,000 -72,500,000 -53,442,000 -60,092,000 -47,608,000 -64,943,000             
      provision for income tax benefit
    		1,537,000 -2,827,000 6,504,000  559,000       -1,458,000 395,000 3,000  5,000   7,000 220,000  8,799,000 -93,000   -49,000 5,552,000 -201,000                  
      net income
    		-4,933,000 61,024,000 3,615,000 54,835,000 -13,579,000 -15,527,000 -12,698,000 -16,529,000 -11,664,000 -8,510,000 -8,950,000 -15,645,000 -22,088,000 -10,362,000 916,631,000 -8,191,000 -25,946,000 -32,034,000 -35,308,000 -52,405,000 -79,679,000 -58,434,000 -73,643,000 -62,887,000 -83,053,000 -65,606,000 -58,431,000 -39,838,000 -72,580,000 -50,186,000 -59,433,000 -40,818,000 -65,087,000 -66,877,000 -66,287,000 -65,319,000 -33,962,000 -47,225,000 -42,150,000 -47,314,000 -47,603,000 -42,474,000 -54,495,000 -58,215,000  
      yoy
    		-63.67% -493.02% -128.47% -431.75% 16.42% 82.46% 41.88% 5.65% -47.19% -17.87% -100.98% 91.00% -14.87% -67.65% -2696.10% -84.37% -67.44% -45.18% -52.06% -16.67% -4.06% -10.93% 26.03% 57.86% 14.43% 30.73% -1.69% -2.40% 11.51% -24.96% -10.34% -37.51% 91.65% 41.61% 57.26% 38.05% -28.66% 11.19% -22.65% -18.73%      
      qoq
    		-108.08% 1588.08% -93.41% -503.82% -12.55% 22.28% -23.18% 41.71% 37.06% -4.92% -42.79% -29.17% 113.16% -101.13% -11290.71% -68.43% -19.00% -9.27% -32.62% -34.23% 36.36% -20.65% 17.10% -24.28% 26.59% 12.28% 46.67% -45.11% 44.62% -15.56% 45.60% -37.29% -2.68% 0.89% 1.48% 92.33% -28.08% 12.04% -10.91% -0.61% 12.08% -22.06% -6.39%   
      net income margin %
    		-27.87% 132.98% 18.08% 209.33% -88.24% -82.79% -75.28% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% 
      net unrealized loss on available-for-sale investments
    		-123,000           -337,000    -17,000 -28,000                -120             
      total comprehensive loss
    		-5,056,000    -13,586,000 -10,194,000 -12,626,000 -16,510,000 -11,640,000   -15,982,000 -22,022,000   -8,208,000 -25,974,000 -41,856,250 -35,302,000 -52,414,000 -79,709,000 -54,901,500 -73,801,000 -63,119,000 -82,686,000 -42,647,250 -58,466,000 -39,673,000 -72,450,000 -41,234 -59,239 -40,489 -65,207 -66,921 -66,263 -65,338 -34,104 -47,170 -41,954 -47,295      
      net income per share
    		-0.1 1.21 0.07 1.09                                          
      shares used to compute net loss per share - basic and diluted
    		51,279                                             
      licensing revenue
    		 1,875,000  7,500,000             2,500,000        1,500,000 10,000,000  18,500,000                  
      impairment of long-lived assets
    		      1,562,000 2,951,000                                      
      net gain on realized contingent milestone and royalty assets
    		   75,137,000                                          
      net unrealized gain on available-for-sale investments
    		 6,250 42,000 -10,000 -7,000 28,750 72,000 19,000 24,000 -52,500 61,000  66,000 -30,250 -76,000   -8,250 6,000 -9,000 -30,000 -5,750 -158,000 -232,000 367,000 65,000 -35,000 165,000 130,000 100.5 194 329   24   55 196 19      
      total comprehensive income
    		 11,224,000 3,657,000 54,825,000      -11,723,250 -8,889,000   220,593,250 916,555,000                               
      shares used to compute net income per share - basic
    		 180 50,520 50,177                                          
      shares used to compute net income per share - diluted
    		 531 51,908 50,726                                          
      provision for income tax expense
    		   -18,371,000  -6,588,000 -2,646,000 -1,308,000 1,262,000 -3,494,000 -1,367,000   3,894,000 -182,362,000  -524,000    -227,000   -39,000 -147,000    -80,000                 
      basic and diluted net loss per share
    		    -0.27 -0.31 -0.26 -0.34 -0.24       -0.11 -0.34 -0.41 -0.48 -0.8 -1.24 -0.91 -1.16 -1 -1.4 -1.17 -1.05 -0.72 -1.32 -0.92 -1.1 -0.76 -1.22 -1.27 -1.27 -1.27 -0.73 -1.06 -1.1 -1.4 -1.42 -1.29 -1.72 -1.83  
      shares used to compute basic and diluted net loss per share
    		    49,706 157 49,038 48,747 48,283       76,270 75,247 1,516 73,574 65,669 64,493 464 63,303 62,861 59,463 165 55,858 55,529 54,938 198 54,248 53,799 53,256 52,611 52,255 51,617 46,470 44,407 38,326 33,689 33,532 32,830 31,754 31,768  
      collaboration revenue
    		         198,000 6,000 6,000 6,000 5,000 6,000 172,000 9,000 2,814,000 2,797,000 1,980,000 3,872,000 7,083,000 7,261,000 5,488,000 6,632,000 9,584,000 8,836,000 7,650,000 5,338,000                 
      restructuring and related expenses
    		           1,169,000 1,574,000 1,411,000 509,000 1,594,000 9,324,000 18,371,000 1,771,000                           
      revenue:
    		                                             
      total revenue
    		       14,256,000 14,503,000 17,565,000 15,693,000 13,749,000 10,417,000 14,649,000 12,451,000 11,050,000 13,196,000 14,946,000 13,194,000 12,914,000 14,257,000 18,730,000 18,257,000 15,008,000 19,862,000 29,499,000 12,427,000 26,150,000 5,338,000 15,737,000 12,838,000 23,476,000 8,319,000 4,275,000 3,509,000 3,087,000 19,075,000 5,471,000 18,410,000 10,698,000 7,134,000 20,401,000 6,336,000 2,974,000 945,000 
      interest income and other income
    		       1,128,000 1,434,000 1,847,000 1,786,000 2,504,000 2,979,000 3,722,000 2,758,000 2,440,000 -375,000                          668,000   
      loss on extinguishment of debt
    		              -3,034,000          -15,464,000                     
      loss from continuing operations before income taxes
    		         -5,016,000 -7,583,000 -14,187,000 -22,483,000 -14,259,000 -16,023,000                               
      net income from continuing operations
    		         -8,510,000 -8,950,000 -15,645,000 -22,088,000 -14,256,000 -16,023,000                               
      income from discontinued operations before income taxes
    		              1,115,016,000                               
      net income from discontinued operations
    		             3,894,000 932,654,000                               
      continuing operations - basic and diluted
    		         -0.19 -0.17 -0.28 -0.35 -0.22 -0.21                               
      discontinued operations - basic and diluted
    		             0.41 12.35                               
      net income - basic and diluted
    		         -0.19 -0.17                                   
      shares used to compute basic and diluted net income per share
    		         -1,984 52,361 56,682                                  
      net loss - basic and diluted
    		           -0.28                                  
      net loss - basis and diluted
    		            -0.35                                 
      shares used to compute basis and diluted net loss per share
    		            62,934                                 
      net income - basis and diluted
    		             0.19 12.14                               
      shares used to compute basis and diluted net income per share
    		             -2,087 75,515                               
      transaction-related legal expenses
    		               3,778,000                              
      income from investment in trc, llc
    		               28,127,000 25,110,000 35,306,000 30,208,000 21,926,000 16,547,000 20,139,000 13,403,000 21,381,000 13,515,000 11,913,000 7,197,000 8,366,000 6,229,000 5,428,000 3,119,000 1,949,000              
      costs and expenses:
    		                                             
      total costs and expenses
    		                   77,024,000 98,149,000 95,220,000 94,872,000 87,184,000 92,338,000 100,071,000 77,628,000 68,626,000 79,004,000 78,358,000 75,288,000 72,180,000 73,295,000 61,272,000 68,630,000 61,916,000 52,569,000 52,968,000 60,052,000 53,793,000 52,427,000 58,138,000 56,398,000 59,680,000 60,963,000 
      mylan collaboration agreement
    		                     8,061,500 10,996,000 9,520,000 11,730,000 9,915,000 3,591,000                   
      product sales
    		                             2,415,000 3,849,000 5,361,000 3,679,000 4,140,000 3,474,000 3,050,000 3,901,000 5,359,000 3,311,000 2,312,000 2,124,000 1,280,000 1,303,000 861,000 945,000 
      cost of goods sold
    		                             632,000 705,000 -1,448,000 826,000 985,000 1,364,000 565,000 332,000 638,000 778,000 581,000 505,000 371,000 369,000 279,000 188,000 
      revenue from collaborative arrangements
    		                             7,936,000 8,989,000 18,115,000 4,640,000 135,000 35,000 37,000 15,174,000 112,000 15,099,000 8,386,000 5,010,000 19,121,000 5,033,000   
      other-than-temporary impairment loss
    		                                             
      provision for income tax
    		                             -1,826,250 -659,000 -6,790,000              
      provision for income taxes
    		                                144,000 868,000 454,000 5,383,000 812,000 36,000 694,000 4,323,000 2,514,000 4,948,000    
      revenue from collaboration agreements
    		                                           2,113,000  
      other income
    		                                           214,000  
      net income and comprehensive loss
    		                                            -60,018,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 
                                                  
        assets
      		                                            
        current assets:
      		                                            
        cash and cash equivalents
      		288,101,000 167,806,000 174,773,000 281,927,000 110,614,000 37,797,000 23,378,000 46,345,000 53,835,000 39,545,000 71,685,000 105,596,000 187,665,000 298,172,000 418,538,000 87,292,000 94,367,000 89,959,000 121,424,000 204,949,000 114,011,000 81,467,000 93,282,000 104,735,000 332,798,000 58,064,000 102,403,000 178,311,000 223,235,000 378,021,000 101,202,000 103,854,000 125,831,000 91,301,000 139,626,000 169,945,000 86,572,000 148,363,000 128,803,000 127,114,000 97,090,000 100,899,000 122,228,000 268,199,000 
        short-term marketable securities
      		106,565,000 147,551,000 154,907,000 56,877,000 20,241,000 50,553,000 67,983,000 49,733,000 46,140,000 62,881,000 62,318,000 61,855,000 53,598,000 29,312,000 68,294,000 45,558,000 53,149,000 83,506,000 94,789,000 60,004,000 95,957,000 211,474,000 265,065,000 333,605,000 154,233,000 222,767,000 217,278,000 217,761,000 210,823,000 127,255,000 199,207,000 249,049,000 292,700,000 243,700,000 222,194,000 222,823,000 143,910,000 101,316,000 51,073,000 68,856,000 113,896,000 135,337,000 162,489,000  
        receivables from collaborative arrangements
      		15,584,000 45,539,000 18,267,000 21,919,000 15,353,000 18,440,000 16,845,000 14,299,000 14,664,000 17,474,000 17,057,000 15,796,000 12,270,000 16,785,000 14,114,000 12,488,000 12,277,000 14,065,000 14,001,000 12,220,000 11,915,000 15,868,000 12,399,000 11,413,000 14,214,000 11,996,000 4,595,000 979,000 7,824,000 10,053,000 3,907,000 3,865,000 2,845,000 11,547,000 5,318,000 7,639,000 22,713,000 35,080,000 37,536,000 19,640,000 25,488,000 19,660,000 181,000 2,000 
        receivables from milestones and royalty assets
      		 50,000,000    50,000,000                                       
        other prepaid and current assets
      		7,384,000 7,564,000 6,750,000 5,571,000 4,056,000 4,204,000 7,677,000 6,284,000 7,569,000 11,603,000 8,996,000 7,777,000 6,281,000 7,682,000 8,127,000 7,080,000 4,542,000 8,561,000 9,943,000 12,353,000 10,037,000 10,359,000 10,308,000 13,124,000 5,491,000 7,087,000 7,132,000 8,857,000 24,928,000 16,564,000 7,029,000 7,641,000 5,326,000 3,462,000 4,030,000 3,566,000 4,319,000 3,550,000 10,165,000      
        total current assets
      		417,634,000 418,460,000 354,697,000 366,294,000 150,264,000 161,067,000 116,480,000 119,307,000 124,294,000 133,541,000 161,690,000 192,003,000 261,338,000 353,464,000 511,718,000 154,729,000 204,636,000 249,870,000 297,172,000 333,180,000 293,071,000 393,341,000 450,724,000 498,386,000 534,218,000 338,488,000 355,652,000 426,038,000 467,233,000 532,823,000 332,606,000 386,693,000 446,818,000 367,133,000 384,882,000 421,504,000 274,035,000 303,125,000 238,752,000 238,239,000 260,226,000 275,556,000 306,711,000 382,733,000 
        long-term marketable securities
      		 11,128,000 3,029,000          18,776,000            5,067,000 4,985,000 24,939,000   11,869,000 20,217,000 18,252,000 16,999,000 99,399,000 136,445,000 147,885,000 58,769,000 52,316,000 34,598,000      
        property and equipment
      		5,539,000 5,895,000 6,257,000 6,641,000 7,028,000 7,418,000 7,788,000 8,142,000 8,717,000 9,068,000 9,288,000 9,553,000 12,103,000 11,875,000 11,884,000 12,531,000 13,236,000 13,657,000 16,003,000 16,583,000 16,944,000 16,422,000 15,430,000 14,433,000 13,905,000 12,644,000 12,189,000 12,662,000 12,899,000 13,176,000 12,415,000 10,677,000 10,329,000 8,618,000 8,679,000 8,251,000 8,832,000 8,811,000 10,119,000 9,513,000 9,609,000 9,305,000 9,356,000 9,624,000 
        operating lease assets
      		23,001,000 24,371,000 25,450,000 26,493,000 27,430,000 28,354,000 29,334,000 31,815,000 35,364,000 36,287,000 37,576,000 38,453,000 39,204,000 40,126,000 39,992,000 41,112,000 39,349,000 39,690,000 40,718,000 41,508,000 42,517,000 43,260,000 44,391,000 45,184,000 46,106,000 46,604,000 46,755,000 47,831,000 48,861,000                
        restricted cash
      		836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 836,000 837,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000 833,000   
        other assets
      		25,303,000 24,880,000 25,191,000 25,771,000 13,824,000 12,286,000 7,467,000 7,729,000 7,896,000 8,067,000 10,000,000 11,585,000 12,093,000 6,899,000 4,866,000 3,303,000 3,194,000 3,228,000 3,297,000 1,325,000 2,304,000 2,451,000 810,000 1,508,000 1,308,000 1,590,000 1,305,000 1,388,000 1,439,000 1,534,000 1,762,000 1,766,000 1,805,000 2,106,000 5,047,000 1,566,000 5,820,000 1,403,000 823,000 921,000 1,017,000 686,000   
        total assets
      		472,313,000 485,570,000 415,460,000 426,035,000 343,582,000 354,161,000 356,105,000 362,029,000 371,307,000 381,999,000 413,590,000 446,630,000 538,550,000 607,400,000 763,496,000 360,761,000 355,359,000 374,819,000 403,109,000 429,251,000 375,108,000 469,057,000 512,188,000 564,330,000 605,409,000 408,826,000 445,337,000 492,447,000 531,265,000 560,235,000 370,964,000 421,364,000 480,108,000 486,159,000 543,886,000 588,039,000 356,289,000 374,488,000 293,125,000 257,506,000 289,479,000 324,901,000 381,705,000 430,588,000 
        liabilities and shareholders' equity
      		                                            
        current liabilities:
      		                                            
        accounts payable
      		1,100,000 2,568,000 2,213,000 1,675,000 2,408,000 2,242,000 1,454,000 1,674,000 1,686,000 1,524,000 2,368,000 1,569,000 2,663,000 1,554,000 5,337,000 3,074,000 1,510,000 3,098,000 8,900,000 10,702,000 6,834,000 6,775,000 6,442,000 10,065,000 6,645,000 4,758,000 8,713,000 3,501,000 5,596,000 9,028,000 3,745,000 3,644,000 5,085,000 5,623,000 6,406,000 3,626,000 5,351,000 7,412,000 9,092,000 5,963,000 6,335,000 4,021,000 5,284,000 9,499,000 
        accrued personnel-related expenses
      		8,730,000 12,592,000 10,330,000 7,259,000 5,386,000 7,019,000 7,842,000 5,774,000 4,475,000 6,443,000 6,578,000 5,371,000 5,030,000 10,314,000 7,560,000 6,958,000 9,560,000 12,796,000 8,635,000 14,635,000 15,624,000 35,238,000 30,472,000 26,757,000 24,708,000 28,180,000 25,801,000 23,495,000 22,097,000 23,803,000 15,893,000 12,150,000 21,989,000 12,714,000 15,800,000 9,131,000 11,887,000 9,020,000 7,824,000 10,222,000 7,793,000 10,433,000 10,886,000 6,482,000 
        accrued clinical and development expenses
      		2,396,000 3,373,000 5,842,000 3,783,000 2,457,000 1,058,000 864,000 1,966,000 1,399,000 2,246,000 3,272,000 4,006,000 5,022,000 4,932,000 4,078,000 7,627,000 8,922,000 17,010,000 20,607,000 19,457,000 30,903,000 28,799,000 26,944,000 25,229,000 22,658,000 17,587,000 10,907,000 7,404,000 9,207,000 11,876,000 14,100,000 14,508,000 16,435,000 20,487,000 26,386,000 28,036,000 23,859,000 22,650,000 23,640,000 6,652,000 6,674,000 6,628,000 9,435,000 13,869,000 
        accrued general and administrative expenses
      		2,522,000 2,052,000 2,699,000 2,459,000 2,520,000 2,987,000 1,379,000 1,959,000 2,476,000 2,900,000 1,903,000 2,874,000 4,586,000 4,020,000 3,749,000 6,052,000 4,412,000 2,898,000 3,854,000 3,269,000 4,954,000 6,048,000                       
        operating lease liabilities
      		10,752,000 10,945,000 10,914,000 10,896,000 10,807,000 10,712,000 4,196,000 4,219,000 4,063,000 3,923,000 9,713,000 9,160,000 7,431,000 6,753,000 692,000 2,624,000 4,054,000 503,000 1,016,000 1,037,000 1,220,000 9,867,000 9,685,000 8,741,000 7,954,000 7,762,000 6,833,000 7,887,000 48,493,000                
        income tax payable
      		5,287,000 5,287,000 4,074,000 26,696,000 5,853,000 5,853,000         120,550,000                              
        other accrued liabilities
      		988,000 1,485,000 1,335,000 1,865,000 2,071,000 2,214,000 1,210,000 864,000 1,073,000 1,241,000 1,510,000 1,542,000 1,428,000 1,118,000 142,000 2,275,000 792,000 1,304,000 1,830,000 1,496,000 1,833,000 2,013,000 6,732,000 7,018,000 6,559,000 6,331,000 6,549,000 6,432,000 15,587,000 10,445,000 11,052,000 8,700,000 11,508,000 9,828,000 8,369,000 8,049,000 4,095,000 4,913,000 4,725,000 4,322,000 3,333,000 7,460,000 4,340,000 4,538,000 
        total current liabilities
      		31,775,000 38,302,000 37,407,000 54,633,000 31,502,000 32,085,000 23,435,000 22,946,000 21,662,000 24,767,000 25,368,000 24,546,000 26,184,000 28,715,000 142,132,000 32,624,000 44,201,000 58,587,000 66,082,000 67,127,000 86,492,000 123,571,000 104,270,000 106,574,000 98,040,000 111,703,000 108,823,000 110,136,000 113,542,000 98,554,000 102,029,000 93,480,000 105,179,000 48,786,000 57,103,000 48,984,000 45,410,000 44,657,000 46,401,000 27,430,000 24,477,000 28,852,000 35,828,000 40,111,000 
        long-term operating lease liabilities
      		29,752,000 31,758,000 33,681,000 35,561,000 37,349,000 39,108,000 40,785,000 42,441,000 43,840,000 45,236,000 41,118,000 42,521,000 43,763,000 45,407,000 51,381,000 50,642,000 47,415,000 52,681,000 54,353,000 57,768,000 57,026,000 47,220,000 47,823,000 47,631,000 47,199,000 47,725,000 48,620,000 48,565,000                 
        future royalty payment contingency
      		32,795,000 32,795,000 32,213,000 31,640,000 30,977,000 30,334,000 29,691,000 29,061,000 28,417,000 27,788,000 27,165,000 26,556,000 25,988,000 25,438,000 24,888,000                              
        unrecognized tax benefits
      		87,153,000 85,679,000 79,165,000 77,805,000 76,484,000 75,199,000 71,563,000 69,007,000 67,075,000 65,294,000 65,955,000 64,987,000 64,191,000 64,191,000 62,661,000                              
        other long-term liabilities
      		244,000 313,000 313,000 1,548,000 1,287,000 1,890,000 4,977,000 4,885,000 5,445,000 5,919,000 7,679,000 7,678,000 7,678,000 1,657,000 1,657,000 2,404,000 2,428,000 2,420,000 2,609,000 1,833,000 2,058,000 1,833,000 9,704,000 9,614,000 9,583,000 21,287,000 8,900,000 14,457,000 14,261,000 24,762,000 28,323,000 28,325,000 36,085,000 26,490,000 18,996,000 18,493,000 8,847,000 3,878,000 3,738,000 2,785,000 2,433,000 1,890,000 986,000  
        commitments and contingencies
      		                                            
        shareholders’ equity
      		                                            
        preferred shares, 0.00001 par value per share...
      		                                            
        ordinary shares, 0.00001 par value per share...
      		1,000 1,000 1,000 1,000 1,000                                        
        additional paid-in capital
      		1,155,215,000 1,156,288,000 1,153,299,000 1,149,123,000 1,145,083,000 1,141,060,000 1,135,599,000 1,131,008,000 1,125,677,000 1,122,164,000 1,146,948,000 1,172,090,000 1,246,506,000 1,295,725,000 1,324,247,000 1,410,415,000 1,400,566,000 1,387,469,000 1,370,402,000 1,358,318,000 1,233,060,000 1,222,818,000 1,206,524,000 1,191,923,000 1,173,204,000 1,024,614,000 1,000,094,000 987,209,000 971,508,000 960,721,000 948,844,000 937,437,000 925,968,000 895,226,000 885,315,000 871,871,000 742,726,000 732,334,000 602,117,000 499,232,000 487,064,000 470,895,000 414,875,000 405,221,000 
        accumulated other comprehensive income
      		-62,000 61,000 32,000 -10,000  7,000 50,000      51,000      14,000 8,000 17,000 47,000 122,000 280,000 512,000 145,000 94,000 129,000         39,000 181,000 126,000 43,000 25,000 31,000  70,000 
        accumulated deficit
      		-864,560,000 -859,627,000 -920,651,000 -924,266,000 -979,101,000 -965,522,000 -949,995,000 -937,297,000 -920,768,000 -909,104,000 -900,594,000 -891,644,000 -875,999,000 -853,911,000 -843,549,000 -1,760,180,000 -1,751,989,000 -1,726,043,000 -1,694,009,000 -1,658,701,000 -1,606,296,000 -1,526,617,000 -1,468,183,000 -1,394,540,000 -1,331,653,000 -1,248,600,000 -1,182,994,000 -1,124,563,000 -1,084,725,000 -1,012,145,000 -961,959,000 -902,526,000 -861,708,000            
        total shareholders’ equity
      		290,594,000 296,723,000 232,681,000 224,848,000 165,983,000 175,545,000 185,654,000 193,689,000 204,868,000 212,995,000 246,130,000 280,161,000 370,559,000 441,800,000 480,578,000                -13,445,000 34,387,000 63,407,000 184,117,000 241,127,000 293,946,000 297,873,000 321,584,000 238,537,000 222,545,000 257,674,000 289,115,000   
        total liabilities and shareholders’ equity
      		472,313,000 485,570,000 415,460,000 426,035,000 343,582,000 354,161,000 356,105,000 362,029,000 371,307,000 381,999,000 413,590,000 446,630,000 538,550,000 607,400,000 763,496,000                370,964,000 421,364,000 480,108,000 486,159,000 543,886,000 588,039,000 356,289,000 374,488,000 293,125,000 257,506,000 289,479,000 324,901,000   
        future contingent milestone and royalty assets
      		    144,200,000 144,200,000 194,200,000 194,200,000 194,200,000 194,200,000 194,200,000 194,200,000 194,200,000 194,200,000 194,200,000                              
        prepaid clinical and development services
      		     73,000 597,000 2,646,000 2,086,000 2,038,000 1,634,000 979,000 1,524,000 1,513,000 2,645,000 2,311,000 4,742,000 10,245,000 13,242,000 15,913,000 18,792,000 20,374,000 20,761,000                      
        tenant improvement payable to sublessee
      		      6,490,000 6,490,000 6,490,000 6,490,000                                   
        accumulated other comprehensive loss
      		       -22,000 -41,000 -65,000 -225,000 -286,000  -15,000 -121,000 -45,000 -28,000            -36,000 -166,000 -331,000 -525,000 -854,000            
        long-term deferred revenue
      		          175,000 181,000 187,000 192,000 199,000 204,000 301,000 310,000 320,000 329,000 339,000 348,000 750,000 1,154,000 8,511,000 6,761,000 14,169,000 13,444,000 21,733,000 26,179,000 22,469,000 34,220,000 45,651,000            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 48,091 and 65,227 shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively
      		                                            
        deferred revenue
      		          24,000 24,000 24,000 24,000 24,000 24,000 98,000 98,000 2,902,000 5,690,000 7,661,000 11,523,000 18,204,000 25,062,000 23,193,000 31,575,000 33,751,000 43,311,000 42,515,000 43,402,000 57,239,000 54,478,000 50,162,000 134,000 142,000 142,000 218,000 662,000 1,120,000 271,000 342,000 310,000 667,000  
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 50,819 and 65,227 shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively
      		          1,000                                  
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 53,694 and 65,227 shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively
      		           1,000                                 
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 60,542 and 65,227 shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively
      		            1,000                                
        amounts due from trc, llc
      		                35,559,000 43,534,000 43,773,000 27,741,000 42,359,000 53,799,000 48,909,000 35,509,000 26,282,000 28,574,000 16,661,000 20,019,000                 
        equity in net assets of trc, llc
      		               148,250,000 94,108,000 67,537,000 45,086,000 35,822,000 19,439,000 12,750,000                       
        accrued interest payable
      		               3,990,000 5,841,000 3,940,000 5,808,000 3,900,000 5,804,000 3,974,000 5,791,000 3,702,000 6,323,000 5,659,000 7,568,000 5,758,000 10,240,000                
        current portion of non-recourse notes due 2035
      		                9,012,000 16,940,000 12,530,000 6,941,000 11,659,000 19,334,000                       
        convertible senior notes due 2023
      		               228,571,000 228,303,000 228,035,000 227,767,000 227,499,000 227,230,000 226,963,000 226,695,000 226,427,000 226,158,000 225,890,000 225,622,000 225,354,000 225,086,000 224,818,000               
        non-recourse notes due 2035
      		               396,125,000 384,161,000 371,359,000 375,570,000 375,069,000 375,181,000 372,873,000 384,482,000 375,266,000 373,854,000                    
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 65,227 and 74,435 shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively
      		             1,000                               
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 67,366 and 74,435 shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively
      		              1,000                              
        liabilities and shareholders' deficit
      		                                            
        shareholders’ deficit
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 76,427 and 74,435 shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively
      		               1,000                             
        total shareholders’ deficit
      		               -349,809,000 -351,450,000 -338,573,000 -323,592,000 -300,374,000 -373,218,000 -303,751,000 -261,536,000 -202,336,000 -157,936,000 -223,840,000 -182,805,000 -137,224,000 -113,252,000                
        total liabilities and shareholders’ deficit
      		               360,761,000 355,359,000 374,819,000 403,109,000 429,251,000 375,108,000 469,057,000 512,188,000 564,330,000 605,409,000 408,826,000 445,337,000 492,447,000 531,265,000                
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 76,081 and 74,435 shares issued and outstanding at march 31, 2022 and december 31, 2021, respectively
      		                1,000                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 74,435 and 64,328 shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively
      		                 1,000                           
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 73,698 and 64,328 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively
      		                  1,000                          
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 73,470 and 64,328 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively
      		                   1,000                         
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 65,218 and 64,328 shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively
      		                    1,000                        
        receivables from licensing arrangements
      		                        1,200,000 10,000,000                   
        tax receivable
      		                       3,986,000 3,972,000 3,682,000 3,664,000    3,131,000 3,143,000 3,324,000 8,070,000           
        current portion of non-recourse notes due 2033
      		                                            
        non-recourse notes due 2033
      		                         9,851,000 8,701,000 12,348,000 8,300,000 229,535,000               
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 64,328 and 57,015 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively
      		                     1,000                       
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 63,956 and 57,015 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively
      		                      1,000                      
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 63,515 and 57,015 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively
      		                       1,000                     
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 63,004 and 57,015 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively
      		                        1,000                    
        accounts receivable
      		                          87,000 111,000 113,000 620,000 3,024,000 3,434,000 1,973,000 1,576,000 1,346,000 1,233,000 873,000 1,856,000 1,527,000 783,000 805,000 565,000 230,000 90,000 
        deferred rent
      		                             7,976,000 7,038,000 6,670,000 5,772,000 3,288,000 3,450,000 3,674,000 4,159,000 4,369,000 4,449,000 4,746,000 4,895,000 5,044,000 5,070,000 4,989,000 
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 57,015 and 55,681 shares issued and outstanding at december 31, 2019 and 2018, respectively
      		                         1,000                   
        short-term restricted cash
      		                          7,496,000                  
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 56,762 and 55,681 shares issued and outstanding at september 30, 2019 and december 31, 2018, respectively
      		                          1,000                  
        income tax receivable
      		                           3,695,000                 
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 56,637 and 55,681 shares issued and outstanding at june 30, 2019 and december 31, 2018, respectively
      		                           1,000                 
        prepaid taxes
      		                            310,000 310,000 314,000 944,000 926,000 289,000 242,000 3,083,000 3,168,000 3,150,000 242,000      
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 56,122 and 55,681 shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively
      		                            1,000                
        inventories
      		                              17,923,000 17,906,000 17,217,000 15,258,000 12,126,000 13,215,000 12,480,000 9,810,000 9,406,000 12,141,000 12,553,000 12,337,000 15,129,000 14,756,000 
        liabilities and shareholders' (deficit) equity
      		                                            
        shareholders’ (deficit) equity
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at december 31, 2018 and 2017, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 55,681 and 54,381 shares issued and outstanding at december 31, 2018 and 2017, respectively
      		                             1,000               
        total shareholders’ (deficit) equity
      		                             -51,589,000               
        total liabilities and shareholders’ (deficit) equity
      		                             560,235,000               
        convertible senior notes
      		                              224,550,000 224,282,000 224,014,000 223,478,000 223,210,000 222,942,000         
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 55,410 and 54,381 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively
      		                              1,000              
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 55,104 and 54,381 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively
      		                               1,000             
        ordinary shares, 0.00001 par value: 200,000 shares authorized; 54,798 and 54,381 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively
      		                                1,000            
        other investments
      		                                  8,000,000 8,000,000 8,000,000 8,000,000 8,000,000 8,000,000     
        liabilities and shareholders’ equity
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at september 30, 2017 and december 31, 2016, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at september 30, 2017 and december 31, 2016; 54,087 and 52,833 shares issued and outstanding at september 30, 2017 and december 31, 2016, respectively
      		                                 1,000           
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at june 30, 2017 and december 31, 2016, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at june 30, 2017 and december 31, 2016; 53,829 and 52,833 shares issued and outstanding at june 30, 2017 and december 31, 2016, respectively
      		                                  1,000          
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at march 31, 2017 and december 31, 2016, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at march 31, 2017 and december 31, 2016; 53,290 and 52,833 shares issued and outstanding at march 31, 2017 and december 31, 2016, respectively
      		                                   1,000         
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at september 30, 2016 and december 31, 2015, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at september 30, 2016 and december 31, 2015; 48,092 and 37,981 shares issued and outstanding at september 30, 2016 and december 31, 2015, respectively
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at june 30, 2016 and december 31, 2015, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at june 30, 2016 and december 31, 2015; 47,853 and 37,981 shares issued and outstanding at june 30, 2016 and december 31, 2015, respectively
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at march 31, 2016 and december 31, 2015, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at march 31, 2016 and december 31, 2015; 41,452 and 37,981 shares issued and outstanding at march 31, 2016 and december 31, 2015, respectively
      		                                            
        prepaid and other current assets
      		                                       9,705,000 10,394,000 6,758,000 6,454,000 3,446,000 
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at september 30, 2015 and december 31, 2014, respectively
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at september 30, 2015 and december 31, 2014; 33,935 and 32,221 shares issued and outstanding at september 30, 2015 and december 31, 2014, respectively
      		                                            
        marketable securities
      		                                        17,794,000 38,521,000 65,638,000 38,231,000 
        liabilities and shareholders’ equity:
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at june 30, 2015 and december 31, 2014
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at june 30, 2015 and december 31, 2014; 33,939 and 32,221 shares issued and outstanding at june 30, 2015 and december 31, 2014
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at march 31, 2015 and december 31, 2014
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at march 31, 2015 and december 31, 2014; 33,802 and 32,221 shares issued and outstanding at march 31, 2015 and december 31, 2014
      		                                            
        liabilities:
      		                                            
        income taxes payable
      		                                          5,216,000  
        shareholders’ equity and parent company deficit
      		                                            
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at september 30, 2014
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at september 30, 2014; 32,228 shares issued and outstanding at september 30, 2014
      		                                            
        parent company deficit
      		                                            
        total shareholders’ equity and parent company deficit
      		                                          339,821,000 384,759,000 
        total liabilities, shareholders’ equity and parent company deficit
      		                                          381,705,000 430,588,000 
        short-term investments
      		                                           80,997,000 
        receivable from theravance, inc.
      		                                           15,243,000 
        deferred revenue, current
      		                                           5,723,000 
        deferred revenue, non-current
      		                                           729,000 
        preferred shares, 0.00001 par value: 230 shares authorized, no shares issued or outstanding at june 30, 2014
      		                                            
        ordinary shares, 0.00001 par value: 200,000 shares authorized at june 30, 2014; 32,260 shares issued and outstanding at june 30, 2014
      		                                            
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 
                                                     
          operating activities
        		                                             
          net loss
        		-4,933,000    -13,579,000 -15,527,000 -12,698,000 -16,529,000 -11,664,000   -15,645,000 -22,088,000   -8,191,000 -25,946,000 -32,034,000 -35,308,000 -52,405,000 -79,679,000 -58,434,000 -73,643,000 -62,887,000 -83,053,000 -65,606,000 -58,431,000 -39,838,000 -72,580,000 -50,186,000 -59,433,000 -40,818,000 -65,087,000 -66,877,000 -66,287,000 -65,319,000 -33,961,000 -47,225,000 -42,150,000 -47,315,000 -47,604,000 -42,474,000 -54,495,000 -58,215,000 -60,018,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                             
          depreciation and amortization
        		381,000 399,000 405,000 409,000 413,000 422,000 429,000 427,000 432,000 392,000 432,000 552,000 625,000 659,000 655,000 1,261,000 1,141,000 1,361,000 1,625,000 1,387,000 1,539,000 1,404,000 1,360,000 1,610,000 2,424,000 1,765,000 1,809,000 1,551,000 1,316,000 858,000 618,000 790,000 900,000 950,000 976,000 1,083,000 791,000 454,000 699,000    1,075,000 686,000 732,000 
          amortization and accretion on investment securities
        		-602,000 -1,310,000 -771,000 -422,000 -327,000 -780,000 -796,000                                       
          future royalty payment contingency interest accretion
        		 582,000 573,000 663,000 643,000 643,000 630,000 644,000 629,000 623,000 609,000 568,000 550,000                                 
          share-based compensation
        		4,504,000 4,480,000 4,576,000 4,543,000 4,877,000 5,826,000 4,963,000 5,375,000 5,229,000 5,824,000 6,262,000 6,264,000 7,021,000 6,950,000 8,530,000 9,709,000 14,545,000 16,918,000 14,370,000 14,941,000 15,832,000 15,551,000 15,564,000 16,585,000 15,276,000 23,912,000 13,019,000 11,299,000 12,220,000 11,714,000 11,746,000 13,855,000 13,998,000 10,685,000 10,398,000 10,269,000 9,895,000 9,904,000 11,330,000 12,250,000 14,663,000 15,626,000 9,350,000   
          amortization of right-of-use assets
        		1,056,000 1,107,000 1,002,000 940,000 966,000 1,053,000 1,129,000 1,131,000 1,101,000 1,428,000 907,000 786,000 1,031,000 1,705,000 970,000 973,000 341,000 1,028,000 1,006,000 1,009,000 743,000 1,131,000 793,000 963,000 457,000 195,000 1,013,000 1,030,000 986,000                 
          deferred income taxes
        		-2,999,000 30,000 994,000 -10,691,000 -1,852,000 -6,589,000 90,000 -561,000 -513,000                                     
          other
        		42,000 6,000 -22,000 -34,000 -39,000             -25,000 203,000 -214,000 46,000 -53,000 -38,000 -13,000 9,000 -2,000 95,000 37,000 16,000 25,000 -47,000 869,000 -890,000  209,000 53,000          
          changes in operating assets and liabilities:
        		                                             
          receivables from collaborative and licensing arrangements
        		29,954,000  3,652,000 -6,566,000 3,087,000 -1,595,000 -2,546,000 365,000 2,810,000 -417,000 -1,261,000 -3,526,000 4,515,000 -2,671,000 -1,626,000 -211,000 1,788,000 -64,000 -1,781,000 -305,000 3,953,000 -3,469,000 -986,000 4,001,000 6,582,000                     
          receivables from milestones and royalty assets
        		50,000,000  0 0 50,000,000                                         
          prepaid clinical and development services
        		 0 0 0 73,000 524,000 2,049,000 -560,000 -48,000 -405,000 -654,000 546,000 -13,000 1,133,000 -334,000 2,431,000 5,503,000 2,997,000 2,671,000 2,879,000 1,582,000 387,000                        
          other prepaid and current assets
        		1,666,000 -814,000 -1,179,000 -1,515,000 148,000 3,473,000 -1,392,000 1,284,000 4,034,000 -2,606,000 -1,220,000 -1,496,000 1,401,000 444,000 -3,767,000 183,000 2,436,000 2,966,000 1,894,000 -2,315,000 322,000 -53,000 3,765,000 -7,631,000 1,592,000 47,000 1,726,000 -272,000 -2,135,000 -1,907,000 2,470,000 -1,385,000 -1,578,000    -770,000         
          right-of-use lease assets
        		314,000 -28,000 41,000 -3,000 -42,000 -73,000 -86,000 -370,000 -178,000 -141,000 -29,000 -35,000 -109,000 -1,837,000 102,000                               
          other assets
        		1,025,000 251,000 -413,000 -1,245,000 330,000 -122,000 241,000 144,000 148,000 -4,542,000 1,558,000 481,000 1,270,000 -2,059,000 -1,598,000 -146,000 1,000 34,000 -2,003,000 932,000 65,000 -1,393,000 614,000 26,000 -99,000 -361,000 1,000   160,000 -74,000     266,000  456,000 255,000       
          accounts payable
        		-1,468,000 355,000 538,000 -733,000 166,000 788,000 -220,000 -2,000 184,000 -348,000 271,000 -919,000 1,002,000 -3,762,000 2,176,000 1,593,000 -1,619,000 -5,740,000 -1,820,000 5,099,000 -1,073,000 1,525,000 -3,879,000 4,858,000 1,154,000 -3,731,000 4,948,000 -2,051,000 -3,440,000 5,240,000 646,000 -1,862,000 -449,000 -1,258,000 2,794,000 2,004,000          
          accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities
        		-4,867,000 -1,275,000 3,606,000 3,192,000 -1,514,000 2,991,000 733,000 1,140,000 -3,396,000 -438,000 -123,000 -2,197,000 -4,337,000 4,379,000 -7,330,000 -791,000 -10,344,000 -652,000 -3,448,000 -15,826,000 -17,299,000 6,161,000 5,575,000 4,796,000 -10,549,000 20,472,000 5,734,000 -8,296,000 -7,284,000 3,808,000 4,725,000 -13,973,000 -5,076,000    2,458,000 14,000 5,718,000    159,000 174,000 4,563,000 
          operating lease liabilities
        		-2,199,000 -1,892,000 -1,862,000 -1,699,000 -1,664,000 4,839,000 -1,680,000 -1,242,000 -1,256,000 -1,672,000 -850,000 487,000 -966,000 87,000 -1,193,000 1,797,000 -1,715,000 -2,185,000 -1,275,000 559,000 1,159,000 -421,000 1,136,000 1,178,000 -293,000 -10,000 -936,000                   
          unrecognized tax benefits
        		1,474,000 6,515,000 1,360,000 1,321,000 1,285,000 3,637,000 2,555,000 1,933,000 1,781,000                                     
          other long-term liabilities
        		-69,000 -1,000 -1,000 1,000 68,000 -575,000 4,000 0 39,000 6,252,000 969,000 794,000 -468,000 -104,000 -404,000 -25,000 8,000 -189,000   224,000 -7,871,000 90,000 31,000 144,000 540,000 -5,557,000 196,000 73,000 -4,911,000 -3,000 -6,411,000 1,267,000 7,481,000 505,000 5,354,000 4,948,000 -82,000 590,000 -640,000 402,000 321,000    
          net cash from operating activities
        		73,279,000 -6,064,000 -6,508,000 208,074,000 43,039,000 -902,000 -5,196,000 -4,415,000 -1,022,000 -854,000 -2,486,000 -12,436,000 -11,221,000 -124,055,000 -22,137,000 -14,730,000 -26,069,000 -42,434,000 -45,446,000 -50,113,000 -69,865,000 -64,925,000 -77,031,000 -53,346,000 -55,101,000 -64,352,000 -44,622,000 -48,030,000 -81,193,000 -52,178,000 -48,977,000 -61,537,000 49,825,000             
          capital expenditures
        		0 -8,000 0 0  -190,000 -15,000 -36,000 -91,000 -677,000 -21,000 -852,000 -938,000 -266,000 57,000 -113,000 -250,000 -444,000 -1,039,000 -156,000 -1,767,000 -1,244,000 -2,050,000 -2,368,000 -954,000 -1,303,000 -77,000 -576,000 -1,220,000 -1,500,000 -1,875,000 -1,094,000 -2,771,000             
          free cash flows
        		73,279,000 -6,072,000 -6,508,000 208,074,000  -1,092,000 -5,211,000 -4,451,000 -1,113,000 -1,531,000 -2,507,000 -13,288,000 -12,159,000 -124,321,000 -22,080,000 -14,843,000 -26,319,000 -42,878,000 -46,485,000 -50,269,000 -71,632,000 -66,169,000 -79,081,000 -55,714,000 -56,055,000 -65,655,000 -44,699,000 -48,606,000 -82,413,000 -53,678,000 -50,852,000 -62,631,000 47,054,000             
          investing activities
        		                                             
          purchases of marketable securities
        		-43,407,000 -64,929,000 -124,746,000 -56,574,000 -1,968,000 -37,721,000 -44,882,000 -31,238,000 -26,902,000 0 0 -1,000 -134,533,000 -9,885,000 -39,497,000 -35,589,000 -18,174,000 -53,531,000 -64,760,000 -39,978,000 -36,000 -64,431,000 -57,061,000 -215,717,000 -64,778,000 -57,486,000 -158,384,000 -59,890,000 -148,138,000 -16,849,000 -64,500,000 -47,073,000 -54,839,000             
          maturities of marketable securities
        		96,000,000 65,525,000 24,500,000 20,350,000 32,600,000 40,051,000 27,498,000 28,243,000 44,021,000 0 0 1,935,000 29,500,000 49,300,000 17,001,000 43,200,000 48,499,000 64,799,000 30,000,000 75,900,000 115,500,000 118,000,000 125,615,000 36,500,000 119,203,000 72,850,000 134,800,000 54,170,000 77,198,000 97,742,000 113,022,000 90,129,000 46,299,000 69,419,000 84,688,000 36,282,000 27,750,000 23,445,000 17,069,000 62,763,000 42,409,000 53,470,000    
          net cash from investing activities
        		52,593,000 588,000 -100,246,000 -36,258,000 30,632,000 15,686,000 -17,399,000 -3,031,000 17,028,000 -677,000 -21,000 11,047,000 -43,046,000 39,161,000 1,075,409,000 7,515,000 31,924,000 10,824,000 -35,793,000 35,766,000 113,697,000 52,368,000 66,539,000 -176,589,000 68,403,000 14,061,000 -23,656,000 -1,296,000 -72,160,000 99,393,000 46,647,000 41,962,000 -11,294,000       62,089,000 41,299,000 42,154,000    
          financing activities
        		                                             
          proceeds from the sale of ordinary shares
        		 0 0 0 20,000 30,000 25,000           0 0   0 0 0 139,915,000                     
          proceeds from option exercises
        		241,000 488,000                0 0 2,000 3,000 401,000 24,000 733,000 203,000 169,000 428,000 2,291,000 254,000 87,000 1,225,000 46,000 35,000 373,000 2,504,000 2,816,000          
          repurchase of shares to satisfy tax withholding
        		-5,818,000 -1,979,000 -678,000 -503,000 -874,000 -528,000 -397,000 -463,000 -1,271,000 -518,000 -512,000 -583,000 -887,000 -993,000 -662,000 -347,000 -1,448,000 -455,000 -2,286,000 -727,000 -5,593,000 -814,000 -987,000 -1,144,000 -6,804,000 -430,000 -562,000 -494,000 -1,687,000 -1,355,000 -1,547,000 -5,190,000 -1,715,000             
          net cash from financing activities
        		-5,577,000 -1,491,000 -400,000 -503,000 -854,000 -365,000 -372,000 -44,000 -1,716,000 -30,609,000 -31,404,000 -80,680,000 -56,240,000 -35,472,000 -722,026,000 140,000 -1,448,000 149,000 -2,286,000 105,285,000 -11,288,000 743,000 -963,000 1,873,000 261,432,000 -1,544,000 -134,000 4,402,000 -1,433,000 229,604,000 -322,000 -2,402,000 -1,680,000         26,044,000    
          net increase in cash, cash equivalents, and restricted cash
        		120,295,000 -6,967,000 -107,154,000 171,313,000 72,817,000   -7,490,000 14,290,000 -32,140,000   -110,507,000 -120,366,000 331,246,000 -7,075,000 4,407,000 -31,461,000 -83,525,000 90,938,000 32,544,000 -11,815,000 -11,453,000 -228,063,000 274,734,000 -51,835,000 -68,412,000 -44,924,000 -154,786,000 276,819,000 -2,652,000 -21,977,000 36,851,000             
          cash, cash equivalents, and restricted cash at beginning of period
        		168,642,000 0 0 0 38,633,000 0 0 0 40,381,000 0 0 0 299,008,000 0 0 0 90,796,000 0 0 0 82,300,000 0 0 0 58,897,000 0 0 0 378,854,000 0 0 0 89,813,000             
          cash, cash equivalents, and restricted cash at end of period
        		288,937,000 -6,967,000 -107,154,000 171,313,000 111,450,000 14,419,000 -22,967,000 -7,490,000 54,671,000 -32,140,000 -33,911,000 -82,069,000 188,501,000 -120,366,000 331,246,000 -7,075,000 95,203,000 -31,461,000 -83,525,000 90,938,000 114,844,000 -11,815,000 -11,453,000 -228,063,000 333,631,000 -51,835,000 -68,412,000 -44,924,000 224,068,000 276,819,000 -2,652,000 -21,977,000 126,664,000             
          supplemental disclosure of cash flow information
        		                                             
          cash paid for income taxes
        		-351,000 6,210,000 12,769,000 8,901,000 4,000 97,000 0 21,000 -9,000 10,000 0 7,000 7,000 117,940,000 1,000   -275,000 -3,826,000   0 0 23,000 -9,000 0 1,000   -2,289,000         9,494,000       
          net income
        		 61,024,000 3,615,000       -8,510,000    -10,362,000                                
          adjustments to reconcile net income to net cash from operating activities:
        		                                             
          loss on disposal of property and equipment
        		 0 0   163,000 -163,000   -1,000 1,000 1,323,000 29,000                                 
          loss on impairment of long-lived assets
        		     0 1,562,000                                       
          receivables from collaborative arrangements
        		                          -3,616,000 6,845,000 2,229,000 -6,146,000 -42,000 -1,020,000 4,264,000  2,321,000 1,437,000 12,367,000      -179,000 88,000 844,000 
          future contingent milestone and royalty assets
        		 0 0                                           
          purchases of property and equipment
        		 -8,000 0   -190,000 -15,000 -36,000 -91,000 -677,000 -21,000 -852,000 -938,000 -266,000 57,000 -113,000 -250,000 -444,000 -1,039,000 -156,000 -1,767,000 -1,244,000 -2,050,000 -2,368,000 -954,000 -1,303,000 -77,000 -576,000 -1,220,000 -1,500,000 -1,875,000 -1,094,000 -2,771,000             
          purchase of derivative
        		                                             
          sale of short-term investments and marketable securities
        		         0 0 8,662,000 62,715,000 12,000                                
          ordinary share repurchases
        		     0 0 0 -445,000 -30,264,000 -30,891,000 -80,543,000 -55,353,000                                 
          proceeds from espp purchases
        		     133,000 0   173,000 -1,000   314,000 1,000   604,000 0   1,156,000 0   869,000 0   1,431,000 0   0   0         
          income tax payable
        		  -22,622,000                                           
          deferred revenue
        		         -199,000 -6,000 -5,000 -6,000 -6,000 -6,000 -171,000 -9,000 -2,815,000 -2,796,000 -1,981,000 -3,871,000 -7,083,000 -7,262,000 -5,488,000 -6,632,000 -9,584,000 -8,835,000 -7,493,000 -5,333,000 -10,042,000 -8,990,000 -7,115,000 95,371,000 5,000 -2,000 17,000 -423,000 -236,000 1,141,000 -163,000 173,000 212,000    
          proceeds from the sale of property and equipment
        		         0 0 1,303,000 210,000 0 0 17,000 1,849,000 0    29,000 34,000                       
          net decrease in cash, cash equivalents, and restricted cash
        		     14,419,000                                        
          supplemental disclosure of non-cash activities
        		                                             
          recognition of tenant improvement allowance assigned to sublease
        		         0 0 0 6,490,000                                 
          amortization and accretion income
        		        -354,000 -403,000 -402,000 -414,000 -678,000 -339,000 -311,000 -33,000 2,000 1,000 -22,000 20,000 11,000 -56,000 -169,000 -318,000 -536,000 -852,000 -903,000 -1,067,000 -629,000                 
          less: net income from discontinued operations
        		             -3,894,000                                
          net loss from continuing operations
        		         -8,510,000 -8,950,000 -15,645,000 -22,088,000 -14,256,000                                
          gain on sale of velusetrag
        		             0 12,000                               
          loss on extinguishment of debt
        		             0        0 0 0 15,464,000                     
          accrued interest payable
        		             0 -1,296,000 -1,851,000 1,901,000 -1,868,000 1,908,000 -1,904,000 1,830,000 -1,817,000 2,089,000 -2,621,000 664,000 -1,909,000 1,810,000                   
          net cash from operating activities - continuing operations
        		         -854,000 -2,486,000 -12,436,000 -11,221,000 54,913,000                                
          net cash from operating activities - discontinued operations
        		             -178,968,000                                
          proceeds from the sale of velusetrag
        		             0                                
          net cash from investing activities - continuing operations
        		         -677,000 -21,000 11,047,000 -43,046,000 39,161,000                                
          net cash from investing activities - discontinued operations
        		             0                                
          proceeds from ampreloxetine funding
        		             0                                
          principal payment on 2035 notes
        		             0    0 0 -5,032,000 -5,698,000                         
          principal payment on 2023 notes
        		             0                                
          net cash from financing activities - continuing operations
        		         -30,609,000 -31,404,000 -80,680,000 -56,240,000 -35,472,000                                
          net cash from financing activities - discontinued operations
        		             0                                
          cash paid for interest
        		             0 7,117,000 10,514,000 4,613,000 13,062,000 3,477,000 8,105,000 14,385,000 3,737,000 0 12,396,000 7,891,000 9,081,000 5,344,000   3,737,000 0   0            
          supplemental disclosure of non-cash investing and financing activities
        		                                             
          gain from lease modification
        		                 0                            
          net decrease increase in cash, cash equivalents, and restricted cash
        		                                             
          undistributed earnings from trc, llc
        		               -18,583,000 -18,596,000 -22,206,000 -25,296,000 -1,765,000 4,751,000                         
          interest payable on 2023 notes
        		                                             
          ampreloxetine interest accretion
        		             550,000                                
          ​
        		                                             
          proceed from issuance of 2035 notes
        		                                             
          gain on disposal of property and equipment
        		              0 122,000 -218,000                             
          repurchases of ordinary shares
        		                                             
          interest shortfall on 2035 notes
        		               2,660,000 4,712,000 0    7,499,000 9,051,000                       
          accounts receivable
        		                         86,000 145,000 -118,000 507,000 2,404,000 410,000 -1,461,000 280,000    983,000 -329,000 395,000     -87,000 196,000 
          tax receivable
        		                     -295,000 337,000   0 0   3,099,000 0 0 5,092,000             
          proceeds from the sale of marketable securities
        		                     14,000 1,000 4,995,000 14,932,000                     
          proceeds from the sale of vibativ business
        		                         0 0                   
          proceeds from issuance of 2035 notes
        		                     0 0 0 380,000,000                     
          payment of issuance costs on 2035 notes
        		                     0 0 -261,000 -5,065,000                     
          payment of redemption premium on 2033 notes
        		                     0 0 0 -11,470,000                     
          principal payment on 2033 notes
        		                     0 0 0 -235,347,000                     
          right-of-use assets obtained in exchange for lease obligations
        		                         0 0 0 49,847,000                 
          net gain from the sale of vibativ business
        		                                             
          inventory
        		                                             
          deferred rent
        		                             938,000 368,000 898,000 2,104,000             
          proceeds from issuance of 2033 notes
        		                                             
          amounts due from trc, llc
        		                      -13,403,000 -9,229,000 2,295,000                     
          other-than-temporary impairment loss
        		                                             
          inventory write-down
        		                                 1,000   0 109,000 10,000       
          prepaid taxes
        		                                    -18,000 -2,908,000 12,522,000       
          inventories
        		                             -1,077,000 -201,000 20,000 -371,000   140,000  23,000 134,000 -241,000      
          proceeds from the sale of fixed assets
        		                         0                    
          proceeds from issuance of notes
        		                                             
          principal payment on notes
        		                                             
          reversal of inventory purchase commitment liability
        		                              0               
          undistributed earnings from investment in trc, llc
        		                          3,356,000 -8,366,000 -6,229,000 -2,349,000 -1,170,000               
          long-term portion of lease liabilities
        		                            -910,000                 
          cash received for income taxes
        		                                4,473,000             
          excess tax benefits from share-based compensation
        		                                             
          proceeds from the sales of fixed assets
        		                             0 0 0 17,000             
          proceeds from sale of ordinary shares
        		                                       -48,000      
          cash received from income taxes
        		                                             
          net cash provided by financing activities
        		                                 -789,000   481,000 120,270,000 26,020,000 -82,000    324,098,000 46,419,000 
          net increase in cash and cash equivalents
        		                                     19,560,000 16,096,000 30,024,000 -3,809,000 11,684,000 -145,971,000   
          cash and cash equivalents at beginning of period
        		                                 0 0 344,709,000 0 0 112,707,000 0 0 89,215,000    
          cash and cash equivalents at end of period
        		                                 -48,325,000 -30,319,000 169,945,000 -61,791,000 19,560,000 128,803,000 30,024,000 -3,809,000 100,899,000 -145,971,000   
          cash paid (received) for income taxes
        		                                 7,912,000            
          receivable from innoviva, inc.
        		                                             
          purchases of property, equipment, and capitalized software
        		                                             
          net cash (used in) provided by investing activities
        		                                             
          net cash (used in) provided by financing activities
        		                                             
          non-cash revenue from collaboration arrangements
        		                                             
          income taxes payable
        		                                             
          net proceeds from sale of ordinary shares
        		                                    17,000 117,422,000 27,802,000       
          proceeds from option exercise
        		                                    1,090,000         
          net (decrease) increase in cash and cash equivalents
        		                                             
          cash (received) paid for income taxes
        		                                    0         
          net cash provided by investing activities
        		                                      16,385,000       
          non-cash revenue from collaborative arrangements
        		                                             
          receivable from theravance, inc.
        		                                          14,535,000   
          prepaid and other current assets
        		                                             
          proceeds from sale of ordinary shares to mylan, net of premium
        		                                       0 0 25,753,000    
          excess tax benefit of share-based compensation
        		                                       -34,000 -151,000 391,000    
          repurchase of restricted stock
        		                                             
          cash and cash equivalents contributed from theravance, inc.
        		                                          0   
          transfers from theravance, inc.
        		                                          0   
          supplemental disclosure of non-cash information
        		                                             
          contribution of net assets, excluding cash and cash equivalents, from theravance, inc.
        		                                          0   
          depreciation
        		                                        595,000 586,000    
          amortization of premium on marketable securities
        		                                        152,000 239,000    
          charge to write-down inventory to net realizable value
        		                                        0 79,000    
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                             
          other non-cash items
        		                                             
          deferred rent expense
        		                                          81,000 98,000 117,000 
          payments received on notes receivable
        		                                             
          supplemental disclosure of noncash information
        		                                             
          purchases of available-for-sale securities
        		                                             
          maturities of available-for-sale securities
        		                                             
          stock-based compensation
        		                                            12,701,000 
          transfers from parent company
        		                                            46,419,000